Optimal and Minimaz Three-stage Designs for Phase II Clinical Trials Considering Response and Tozicity
The main objective of a phase II trial is to assess the activity of a treatment or drug. On the other hand, we may also need to consider its safety at the same time. Jin (2007) proposed a two-stage design that controls the type I errors of response and toxicity rate separately. In this article, we extend Jins ideas to three-stage designs and propose optimal and minimax designs for three-stage phase II trials, which set the two type I errors at different levels. It shows that a lot could benefit from three-stage designs in contrast to two-stage designs.
Three-stage Designs Optimal Design Minimaz Design Type I Error Mazimum Ezpected Sample Size
JIN Hua YUAN Peng
School of Mathematical Sciences, South China Normal University, P.R.China, 510631
国际会议
2009 International Institute of Applied Statistics Studies(2009 国际应用统计学术研讨会)
青岛
英文
1-4
2009-07-25（万方平台首次上网日期，不代表论文的发表时间）